PhaseBio Pharmaceuticals, Inc.
PHASQ
Other OTC0.00
USD
+0.00
- -
CIK
0001169245
ISIN
US7172241090
CUSIP
717224109
Return %
Stock
S&P500
1Y
-99.99
18.99
3Y
-100.00
64.75
5Y
-100.00
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jonathan P. Mow MBA
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Great Valley Parkway Malvern PA United States of America 19355
- IPO Date
- Oct 18, 2018
- CIK
- 0001169245
- Website
- phasebio.com
- Similar Companies
- Business
- PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. Its main product pipeline includes bentracimab (PB2452), a reversal agent for the antiplatelet therapy ticagrelor used in major bleeding or urgent surgery; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist designed to treat pulmonary arterial hypertension (PAH); and PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The company employs its proprietary elastin-like polypeptide (ELP) technology platform to extend the half-life and improve the pharmacokinetics of its therapeutic candidates. PhaseBio operates primarily in the United States with headquarters in Malvern, Pennsylvania, and a presence in San Diego, California. Founded in 2002, the company targets orphan and severe cardiopulmonary conditions with unmet medical needs. Recent major changes include the sale and transfer of assets related to bentracimab (PB2452) to SFJ Pharmaceuticals in late 2022 following PhaseBio's Chapter 11 bankruptcy filing in October 2022. SFJ Pharmaceuticals, with expertise in global drug development and regulatory activities, assumed responsibility for advancing bentracimab toward U.S. regulatory approval expected by 2024. Additionally, PhaseBio has expanded its product pipeline through the acquisition of novel aldosterone synthase inhibitor assets from Viamet Pharmaceuticals, notably PB6440, enhancing its portfolio in resistant hypertension. The company continues to focus on advancing pemziviptadil (PB1046) for PAH treatment with orphan drug designation from the FDA. PhaseBio's strategic shift involves divesting the bentracimab program to concentrate on the development of remaining pipeline candidates and leveraging its ELP platform for extended-release therapies. PhaseBio targets healthcare providers and patients within the cardiovascular and rare pulmonary disease markets, leveraging its innovative drug development platform to address high unmet medical needs with sustainable and improved treatment options. The company's clinical development efforts encompass multiple ongoing trials aimed at regulatory approval and commercialization of its pipeline products. This profile reflects its transition following financial restructuring and asset realignment to focus on core therapeutic areas and technology platforms.